ArticleNature communications2026
Cryo-EM structure of ex vivo Sup35 yeast prion and the factors defining prion phenotype.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Human prions and amyloids exhibit structural diversity that correlates with different pathological manifestations. Yeast prions represent a convenient model for studying fundamental properties of prions and their strain diversity. The Sup35 yeast prion has multiple structural variants, divided into "strong" and "weak" groups differing in frequency of fibril fragmentation and resulting nonsense-suppression. The molecular origin of these distinctions remains unclear. Here, we show that the different frequency of prion fragmentation is determined by their stability, rather than the efficiency of chaperone binding. The fully protease-resistant part (residues 2-32) of the Sup35 prion core is a key for the prion phenotype and maintenance, whereas partially resistant part (33-72) is less important. We established the cryo-EM structure of a strong Sup35 prion variant purified from yeast, comprising residues 2-64, with 2.7 Å resolution. Comparison of this structure with that of Sup35 amyloid formed in vitro at 4˚C revealed their significant difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.